From Plague to the Promise: The Journey of Bacille Calmette-Guérin

Overview

Journal Bladder (San Franc)

Date 2025 Feb 13

PMID 39944512

Authors

Anthony Kluemper

Kosta Morris

Matthew J Mellon

Affiliations

Soon will be listed here.

Abstract

Background: Intravesical Bacille Calmette-Guérin (BCG) therapy is a widely adopted treatment for non-muscle-invasive bladder cancer (NMIBC). Despite its extensive use, the historical origins of BCG therapy remain under-appreciated by many practitioners. Initially developed as a tuberculosis vaccine by Albert Calmette and Camille Guérin in the early 20 century, BCG's immunomodulatory potential was later harnessed for cancer treatment. The unintended discovery of its attenuated virulence, combined with extensive subsequent research, laid the foundation for its clinical application in bladder cancer. Currently, BCG is a cornerstone treatment for NMIBC, particularly in high-risk cases, and has significantly influenced the evolution of modern immunotherapies, including checkpoint inhibitors.

Objective: This paper was written with the intent of exploring the origins of BCG and historically significant research that led to it's use and acceptance as a treatment for NMIBC while highlighting it's impact on the development of immunotherapy as a whole.

Conclusion: The BCG vaccine's journey from a tuberculosis preventive to a groundbreaking cancer treatment underscores the interconnected nature of scientific discovery and its enduring impact on modern medicine.

References

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

Lobo N, Brooks N, Zlotta A, Cirillo J, Boorjian S, Black P . 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021; 18(10):611-622. PMC: 8204595. DOI: 10.1038/s41585-021-00481-1. View

Morales A, Eidinger D, Bruce A . Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors. J Urol. 2016; 197(2S):S142-S145. DOI: 10.1016/j.juro.2016.10.101. View

Peng M, Xiao D, Bu Y, Long J, Yang X, Lv S . Novel Combination Therapies for the Treatment of Bladder Cancer. Front Oncol. 2021; 10:539527. PMC: 7873600. DOI: 10.3389/fonc.2020.539527. View

Luca S, Mihaescu T . History of BCG Vaccine. Maedica (Bucur). 2013; 8(1):53-8. PMC: 3749764. View

Del Giudice F, Asero V, Bologna E, Scornajenghi C, Carino D, Dolci V . Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. Cancers (Basel). 2023; 15(7). PMC: 10093360. DOI: 10.3390/cancers15071937. View

Jiang S, Redelman-Sidi G . BCG in Bladder Cancer Immunotherapy. Cancers (Basel). 2022; 14(13). PMC: 9264881. DOI: 10.3390/cancers14133073. View

Smith S, Zaharoff D . Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy. 2016; 8(3):351-65. PMC: 5618954. DOI: 10.2217/imt.15.122. View

Coley W . The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 2009; 3(Surg Sect):1-48. PMC: 1961042. View

10.

Zbar B, Rapp H . Immunotherapy of guinea pig cancer with BCG. Cancer. 1974; 34(4 Suppl):suppl:1532-40. DOI: 10.1002/1097-0142(197410)34:8+<1532::aid-cncr2820340827>3.0.co;2-h. View

11.

Cho T, Khatchadourian C, Nguyen H, Dara Y, Jung S, Venketaraman V . A review of the BCG vaccine and other approaches toward tuberculosis eradication. Hum Vaccin Immunother. 2021; 17(8):2454-2470. PMC: 8475575. DOI: 10.1080/21645515.2021.1885280. View

12.

Lamm D, Morales A . A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. Vaccine. 2021; 39(50):7308-7318. DOI: 10.1016/j.vaccine.2021.08.026. View

13.

Morales A, Eidinger D, Bruce A . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2):180-3. DOI: 10.1016/s0022-5347(17)58737-6. View

14.

Muthigi A, George A, Brancato S, Agarwal P . Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol. 2016; 8(3):203-14. PMC: 4872187. DOI: 10.1177/1756287216628784. View

15.

Old L, CLARKE D, Benacerraf B . Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959; 184(Suppl 5):291-2. DOI: 10.1038/184291a0. View